Evaluation of alendronate efficacy on bone mineral density in thalassemic patients

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 6, Issue 4, 2012, Pages 20-24

  Shirani, Fatemeh ^a   Lashkari, Mahin ^a   Ahmadi, Ali Shahriari ^a   Arabi, Mohsen ^a   Asefi, Nastaran ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alendronate; BMD; Osteoporosis; Thalassaemia

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CALCIUM BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; THALASSEMIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84874528272     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. David J Weatherall. Disorder of globin synthesis: the thalassaemias. Williams Hematology, seventh Ed. 2006:633-666
2. Caterina B, Organa P, Renzo G. Thalassaemias and related disorder. Wintrobes clinical hematology eleventh Ed. 2004, 1319-1365
3. Nelson B, Watt S. Treatment of osteoporosis with Bisphosphonates. Endocrinol Metab Clin north Am 1998, 27: 418-439
4. Lasco A, Morabito N, Gaudib A, et al. Effect of hormonal rreplacement therapy on bone metabolism in young adult with beta- thalassaemia major. Osteoporosis Int 2001; 12: 570-575.
5. Christoforidis A, Kazantzidou E, Tsatra H, et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with betathalassaemia major. Hormons (Athens) 2007; 6(4): 334-40.
6. Morbito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassaemia - induced. osteoporosis int 2002; 13: 644-649.
7. Voskari Dou E, Terpos E, Spina G. Pamidronate is an effective treatment for osteoporosis in patients with B - thalassaemia. Br. J Heamatol 2003: 123: 730-737.
8. Christoforidis A, Perifanis V, Papadopoulou E, et al. Poor correlations between measurements of bone quality by Quantitative Ultrasound Sonography (QUS) and Dual energy X-ray Absorptiometry (DXA) in Patients with beta-thalassaemia major. Eur J Haematol. 2008 Sep 17.
9. Shamshirsaz AA, Bekheirnia MR, kamgar M, et al. Bone mineral density in Iranian adolescents and young adults with beta-thalassaemia major. Pediatr-Hematol Oncol. 2007, 24(7):469-79.
10. Voskaridou E, Christolas D. Konstantinidou M, et al. Contineous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassaemia-induced osteoporosis: long-term follow-up of a randomized, placebocontrolled trial. Haematologica 2008, 93(10):1588-90.
11. Voskaridou E, Anagnostopolus A,Constantopolus K. Zoledronic acid for the treatment of osteoporosis in patients with B - thalassaemia. J. Hematologica 2006; 91: 1193-1202.